In their bid to find the best combination of therapies to treat anaplastic thyroid cancer, John A. Copland III, Ph.D., and a team of researchers at Mayo Clinic's campus in Florida demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.

Dr. Copland discusses the trial of the PPAR-gamma agonist efatutazone combined with paclitaxel, plus newer findings with HDAC inhibitors combined with paclitaxel — a combination therapy not yet in trial.

For more information

• Marlow LA, et al. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection. Endocrine-Related Cancer. 2015;22:777.

• Clinical trials: Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer. Mayo Clinic.